secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001104659-24-033015
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio reports FY2023 net loss of $51.6M; cash drops to $7.0M; MB-106 data positive
--------------------------------------------------------------------------------

- Cash and cash equivalents $7.0M at Dec 31, 2023, down from $76.7M at Dec 31, 2022; $30.4M debt termination payment in 2023.
- Net loss $51.6M ($6.00/share) vs $77.5M ($10.09/share) in 2022; R&D spend $40.5M vs $62.5M.
- MB-106 Phase 1/2 multicenter trial: 100% ORR in FL (n=5 all CR) and WM (n=3 with VGPR/PR); no severe CRS/ICANS.
- Registrational trial in Waldenstrom macroglobulinemia planned H2 2024; topline expected H2 2026; RMAT designation request H1 2024.
- Closed uBriGene asset sale for $6M upfront; $5M contingent; lease assignment subject to CFIUS review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000110465924033015/0001104659-24-033015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000110465924033015/tm248266d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-033015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer